Last Updated : October 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Trisenox | Arsenic Trioxide | Acute Promyelocytic Leukemia | Reimburse | Complete | ||
Triumeq | Dolutegravir / abacavir / lamivudine | HIV Infection | List with criteria/condition | Complete | ||
Trodelvy | sacituzumab govitecan | HR+, HER2− advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Trodelvy | sacituzumab govitecan | Locally advanced or metastatic triple-negative breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Trosec | Trospium chloride | Bladder, overactive | List with clinical criteria and/or conditions | Complete | ||
Trulicity | dulaglutide | Diabetes mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
Truqap | capivasertib | HR-positive, HER2-negative locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Active | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV-1 infection, pre-exposure prophylaxis | Reimburse with clinical criteria and/or conditions | Complete | ||
Truvada | Emtricitabine/tenofovir disoproxil fumarate | HIV infection | List with clinical criteria and/or conditions | Complete |